Overview

Biologics and Blistering

Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to answer: how do inflammation and anti-inflammatory skin therapies work in the skin? Inflammation is a protective response from the body's immune system to injury, disease, or irritation. It is a process by which your body's white blood cells and the things they make protect you from infection from outside invaders such as bacteria and viruses.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
John Harris
Treatments:
Adalimumab
Betamethasone
Betamethasone benzoate
Betamethasone sodium phosphate
Betamethasone Valerate
Betamethasone-17,21-dipropionate
Fluticasone
Squaric acid dibutyl ester
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Ustekinumab
Xhance
Criteria
Inclusion Criteria:

- Healthy adult subjects over the age of 18 years with no skin diseases

- Patients with dermatologic conditions such as atopic dermatitis, history of localized
non-melanoma, keratinocytic skin cancer

- Patients with previous clinical patch testing

- UMass Medical School students and employees are eligible to participate.

- Non-English-speaking individuals are also eligible with the assistance of an
interpreter and an approved short form consent in the appropriate language.

Exclusion Criteria:

- Adults unable to give consent

- History of the following specific dermatologic conditions (which would be confounders
due to their particular immunologic etiologies, specifically the TNFa and IL-17
pathways which oppose the Th2 pathway): pityriasis rubra pilaris and psoriasis

- Patients actively receiving whole body phototherapy

- Patients actively receiving systemic broad-spectrum immunosuppression (prednisone,
mycophenolate mofetil, azathioprine, methotrexate)

- Any history of poor wound healing

- History of uncontrolled diabetes

- History of easily torn skin

- Any known cardiac arrhythmia or history of heart failure

- History of demyelinating disease

- History of liver disease or alcohol abuse

- History of melanoma

- Pregnant women

- Individuals who are high risk for tuberculosis including prisoners, immigrants from
TB- endemic areas, or US-based travelers who have visited TB-endemic areas

- Individuals with a self-reported personal history of infection with latent or active
tuberculosis, HIV, Hepatitis B, or Hepatitis C will not be included, because the type
of immunotherapies that will be used in this study may interfere with these
conditions.

- For similar reasons, we will not be including individuals with signs of current or
active infection, self-reported personal history of recurrent infections, or
conditions that compromise the immune system, such as patients with malignancy (except
non- melanoma, keratinocytic skin cancers).